Elypta pursues the missing dynamic biological signal that unlocks risk testing at scale.
Focusing screening, surveillance and prevention on those most likely to benefit allows us to expand these life-saving interventions.
We are pioneering a metabolism-based liquid biopsy.
Our mission is to prevent cancer mortality through early detection.
Elypta is pioneering precise, standardized and scalable profiling of glycosaminoglycans — the GAGome — in biofluids
Elypta offers an opportunity to monitor this dynamic biological signal — independent of age, genetics and clinical history. Our ultimate aim is to reliably identify elevated cancer risk years before diagnosis and enable risk-stratified screening. As glycosaminoglycans have broader relevance, we are making our GAGome kits available for research use.
Learn more about our products →
.svg)
ISO 13485:2016 certified for Design, development and manufacture of in vitro diagnostic test kits and software for the measurement and interpretation of glycosaminoglycans (GAGs) in human biofluids
